Tag Archives: Could

U.S. focus on Pfizer production could delay manufacturing of other COVID-19 vaccines, Serum Institute CEO warns

The U.S.’ move to lock up raw materials and supplies for Pfizer’s COVID-19 vaccine could spell trouble for manufacturers working on other shots around the globe.  The world’s largest vaccine maker by volume, Serum Institute of India, sees bottlenecks ahead, thanks to a U.S. law blocking exports of certain materials needed to produce COVID-19 shots. The… Read More »

‘Why friends with Covid but no symptoms could be less infectious’

How infectious are people who test positive for Covid-19 but have no symptoms? And what is their contribution to the transmission of live virus? These questions are explored by Allyson Pollock, professor of public health at Newcastle University, who’s always candid and unafraid to say it like it is. She and Newcastle colleague, ­independent researcher… Read More »

Capping hospital prices could save $235B annually, Rand study says

Dive Brief: Aggressively regulating the prices of hospital services could reduce healthcare spending by more than $ 235 billion a year, according to a new study issued by the think tank Rand. The report also examines price transparency and increased market competition among hospitals, and concluded that setting fixed prices would save the most money. … Read More »

US HIV infections could drop by 94% before 2030, if treatment is prioritised

Modelling estimates suggest that new HIV infections in the US could be reduced by as much as 94% before 2030, if the current HIV prevention budget is spent more efficiently. Priorities would be linking those diagnosed with HIV to care, ensuring that they receive treatment and getting them to the point of viral suppression. Less… Read More »